Aricept weakness erodes Eisai profits; Small businesses take stand against Express-Medco deal;

@FiercePharma: Discounts, dealmaking and OTC plans: Pfizer aims to hang onto as much Lipitor as possible. Story | Follow @FiercePharma

> Declining sales of the Alzheimer's drug Aricept weighed on Eisai's first-half profits; the Japanese drugmaker posted a 17% decline in net income. Story

> A small business advocacy group is writing Federal Trade Commission officials to protest the pending merger of Express Scripts and Medco Health Solutions. News

> Generics maker Par Pharmaceutical ($PRX) reported earnings of 74 cents per share, slightly higher than analysts had expected, aided by strong sales of its blood pressure drug Metoprolol. Item

> Wholesaler AmerisourceBergen posted higher-than-expected earnings for the fourth quarter, fueled by strong generic sales and specialty-drug revenues. Article

> Watson Pharmaceuticals ($WPI) hiked its full-year forecast after strong contraceptives sales helped deliver a 39% increase in generics revenue. News

> Endo Pharmaceuticals is moving to a new headquarters in Malvern, PA, by the end of the year. Story

> GlaxoSmithKline ($GSK) had its shares upgraded to Outperform by Cowen and Company analyst Steve Scala, who calls the company's growth prospects "solid." Report

> The number of annual deaths from prescription-painkiller overdoses has nearly quadrupled over a decade as the drugs became more common and easier to obtain. Story

> Vietnamese drugmaker Ha Tay Pharmaceutical was only able to sell 20% of its 6.7 million-share stock issue, all of it purchased by existing shareholders. Item

Biotech News

@FierceBiotech: Medical experts argue in favor of beleaguered AZ/BMS diabetes drug dapagliflozin. Item | Follow @FierceBiotech

@JohnCFierce: Exelixis has always had problems with study designs; source of issue with BMS. Fight the FDA, though? Shares tank. Piece | Follow @JohnCFierce

@RyanMFierce: UK drug delivery co Oxford Pharmascience has raised £1.1M for Brazil biz and generics Article | Follow @RyanMFierce

@MaureenFierce: Sanofi set to rev past Pfizer in pharma rankings. Report | Follow @MaureenFierce

> Pharmasset shares continue rise on PhIII plan for interferon-free PSI-7977. News

> Medical experts argue in favor of beleaguered AZ/BMS diabetes drug. Article

> Report: Sanofi alerts U.S. workers to new layoffs in R&D restructuring. Story

Medical Devices News

> Medtronic unveils procedure for minimally invasive spinal fusion. More

> BD falls after failing to meet profit forecast expectations. Report

> Abbott gets nod for Xience Prime. Story

> Medtronic CoreValve study initiated in Japan. Item

> Wright Medical sees net sales decline 3%. Piece

> Axis-Shield, CVS Caremark's MinuteClinic ink deal. Item

Drug Delivery News

> InflammaGen combats "self-digestion" with new delivery and treatment system. More

> Access Pharma tapping investors for $5.2M. Article

> SurModics selling drug delivery unit to Evonik for $30M. News

> Pacira's FDA nod marks win for extended-release tech. Report

> NanoSmart targets tiny 'bubbles' of cancer drugs to childhood tumors. More

> VC-backed Pulmatrix touts inhaled drug tech's delivery of Advair. Article

And Finally... Exercise can cut the risk of obesity even in genetically predisposed people. News

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.